Cryo-Trojan Mesenchymal Stem Cells as Non-Living Tumor-Homing Supercarriers for Enhanced Drug Delivery and Immune Activation in Prostate Cancer
Materials Today Bio,
Год журнала:
2025,
Номер
32, С. 101650 - 101650
Опубликована: Март 12, 2025
Prostate
cancer
remains
a
leading
cause
of
cancer-related
mortality,
with
conventional
therapies
limited
by
systemic
toxicity
and
poor
tumor
targeting.
Developing
innovative
drug
delivery
systems
that
enhance
therapeutic
specificity
while
minimizing
off-target
effects
is
critical.
We
engineered
cryo-trojan
human
umbilical
cord
mesenchymal
stem
cells
(CT-MSCs)
as
non-living,
tumor-homing
carriers
for
mitoxantrone
(MTX),
termed
CT-MTX.
Cryo-treatment
preserved
structural
integrity
chemokine
receptors
(CXCR4/CCR2)
targeting
eliminating
proliferative
risks.
Comprehensive
evaluations
included
loading/release
kinetics,
in
vitro
suppression,
immunogenic
cell
death
(ICD)
induction,
vivo
efficacy/safety
prostate
models.
CT-MTX
demonstrated
superior
loading
(116.38
μg/106
cells)
pH-sensitive
release
(74.10
%
at
pH
5.5),
outperforming
exosomes,
liposomes,
living
MSCs
stability
tumor-specific
delivery.
Compared
to
liposomes
(low
targeting)
nanomaterials
(biocompatibility
concerns),
leveraged
MSC-derived
tropism
without
tumorigenic
In
vitro,
inhibited
proliferation
(84.83
MTX
uptake),
migration
(4.42
residual
migration),
induced
apoptosis
(43.23
late
apoptosis).
Mechanistically,
triggered
ICD
via
PAMPs
release,
activating
CD8+
T
suppressing
immunosuppressive
Treg.
vivo,
selectively
accumulated
tumors,
reducing
growth
87.88
extending
survival
(93.30
vs.
66.70
controls)
negligible
toxicity.
Proteomics
revealed
enriched
immune
pathways
like
NK
cytotoxicity,
validating
its
dual
role
direct
killing
activation.
represents
novel,
non-proliferative
platform
combines
the
capacity
enhanced
safety
controlled
inducing
ICDs
other
immunologically
"cold"
tumors
improve
infiltration.
Язык: Английский
Polyallylamine Hydrochloride-Modified Bovine Serum Albumin Nanoparticles Loaded with α-Solanine for Chemotherapy of Pancreatic Cancer
International Journal of Nanomedicine,
Год журнала:
2025,
Номер
Volume 20, С. 4235 - 4255
Опубликована: Апрель 1, 2025
α-Solanine
(α-Sol)
shows
promise
for
pancreatic
cancer
(PC)
treatment
by
inhibiting
PC
cell
proliferation,
migration,
and
invasion.
However,
its
clinical
application
is
hindered
poor
tumor
targeting,
significant
toxicity,
undesirable
pharmacokinetics.
To
address
these
issues,
this
study
developed
a
nanoparticle
delivery
system
(PBSO
NPs)
using
bovine
serum
albumin
as
carrier,
with
polyallylamine
hydrochloride
surface
modification
to
enhance
α-Sol
delivery.
PBSO
NPs
were
characterized
transmission
electron
microscopy,
dynamic
light
scattering,
size
analyzers,
Fourier-transform
infrared
spectroscopy.
Their
in
vitro
drug
release
profile
cellular
uptake
capabilities
evaluated.
Furthermore,
experiments
conducted
mouse
cells
(Panc02)
investigate
the
effects
of
on
Panc02
viability,
invasion,
apoptosis.
Additionally,
xenograft
model
was
established
vivo
explore
impact
growth.
This
successfully
favorable
morphology
physiological
stability,
capable
enhancing
uptake.
In
demonstrated
that
significantly
inhibited
invasion
while
promoting
Moreover,
enhanced
inhibitory
cells.
further
confirmed
improved
therapeutic
efficacy
against
partially
reducing
toxicity.
exhibited
good
biocompatibility.
apoptosis,
thereby
suppressing
progression
PC.
provides
promising
strategy
treatment.
Язык: Английский